ReviewHealthcare (Basel, Switzerland)2021

Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients.

Giulia Radi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.